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Glucagon like peptide-1 (GLP-1) and serotonin are both involved in food intake regulation. GLP-1 release is stimulated upon nutrient interaction with G-
protein coupled receptors by enteroendocrine cells (EEC), whereas serotonin is released from enterochromaffin cells (ECC). The central hypothesis for the
current study was that nutrient-induced GLP-1 release from EECs is modulated by serotonin through a process involving serotonin receptor interaction.
This was studied by assessing the effects of serotonin reuptake inhibition by fluoxetine on nutrient-induced GLP-1, PYY and CCK release from isolated pig
intestinal segments. Next, serotonin-induced GLP-1 release was studied in enteroendocrine STC-1 cells, where effects of serotonin receptor inhibition were
studied using specific and non-specific antagonists.
Casein (1% w/v), safflower oil (3.35% w/v), sucrose (50 mM) and rebaudioside A (12.5 mM) stimulated GLP-1 release from intestinal segments, whereas
casein only stimulated PYY and CCK release. Combining nutrients with fluoxetine further increased nutrient-induced GLP-1, PYY and CCK release.
Serotonin release from intestinal tissue segments was stimulated by casein and safflower oil while sucrose and rebaudioside A had no effect. The combination
with fluoxetine (0.155 μM) further enhanced casein and safflower oil induced-serotonin release.
Exposure of ileal tissue segments to serotonin (30 μM) stimulated GLP-1 release whereas it did not induce PYY and CCK release. Serotonin (30 and 100 μM)
also stimulated GLP-1 release from STC-1 cells, which was inhibited by the non-specific 5HT receptor antagonist asenapine (1 and 10 μM).
These data suggest that nutrient-induced GLP-1 release is modulated by serotonin through a receptor mediated process.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Serotonin; GLP-1; nutrients; rebaudioside A; small intestine1. Introduction
Gastro-intestinal (GI) hormones play major roles in the regulation
of food intake, gastric emptying and GI motility. In the small intestine
hormones are secreted by enteroendocrine cells (EEC) [22], and are
involved in modulating feelings of satiety and satiation using feed-
back mechanisms to reduce food intake [6,22]. Well-known satiety
inducing hormones are cholecystokinin (CCK), peptide YY (PYY) and
glucagon like peptide-1 (GLP-1). The release of these hormones
involves interaction between nutrients and G-protein coupled
receptors (GPCR) or ion-dependent transporters that are expressed
on EECs [22].
Recently it was found by our group that nutritional and non-
nutritional stimuli such as a lipidmixture (safﬂower oil), carbohydrate
(sucrose), protein (casein) and a non-caloric sweetener (rebaudioside
A) induce GLP-1 and PYY release from ileal tissue segments [24].
Additionally, when these ‘non-predigested’ macronutrients are deliv-⁎ Corresponding author at: Utrechtseweg, 48, 3704 HE Zeist, The Nether-
lands. Tel.:+31 88 866 1768; fax: +31 88 866 8701.
E-mail address: dina.ripken@tno.nl (D. Ripken).
http://dx.doi.org/10.1016/j.jnutbio.2016.03.006
0955-2863/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under tered to the ileum by a nasoileal feeding tube, they activate satiety
signals, increase satiety hormone release and decrease subsequent
food intake in healthy volunteers [29]. The mechanism of how these
different nutrients delivered to the ileum cause satiety hormone
release remains to be investigated.
It is known that lipids are sensed in the formof long and short chain
fatty acids by free fatty acid receptors. Carbohydrates are predomi-
nantly sensed as glucose, possibly via the Na+ dependent sodium/
glucose cotransporter member 1 (SGLT-1) or by the so-called sweet
taste receptor, a G-protein coupled heterodimer (T1R2/T1R3).
Proteins are mainly detected after being digested into amino acids,
di- and tripeptides by the G-coupled calcium sensing receptor (CaSR),
umami taste receptor dimer T1R1/T1R3, GPCR6A, and peptide
transporter 1 (PEPT1) [16,22]. However, not for all nutrients
stimulating GLP-1, PYY or CCK release, a receptor is known. There
may be additional mechanisms allowing to respond to ﬂuctuations in
intestinal nutrient levels [9]. One such mechanism may involve
paracrine cell–cell interaction via serotonin release from enterochro-
mafﬁn cells (ECC).
Although it is known that serotonin is involved in food intake
regulation [30], it is still unknown how serotonin stored in the smallhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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throughout the gut in the duodenum, jejunumand ileumand stored in
dense core granules located in the basal and apical part of ECCs. These
cells are responsible for the production and storage of approximately
90% of the total pool of serotonin in the body [3,12]. The release of
serotonin from ECCs is stimulated by some dietary compounds in vitro
[14] and some dietary compounds have been shown to activate the 5-
HT2c receptor in vitro [19]. Several serotonin receptor subtypes are
expressed in the small intestine, enteric neurons and enterocytes express
5-HT1, 5-HT2, 5-HT3, 5-HT4 and 5-HT7 receptors. Activation of these
receptors has various effects such as neurotransmitter release, controlling
motility, intestinal secretion and contraction or relaxation [8].
The present study aimed to investigate to what extent serotonin is
involved in nutrient-stimulated GLP-1 release when nutrients are
delivered to the ileum. It was hypothesized that nutrients stimulate
serotonin release from ECCs, which consequently stimulates GLP-1
secretion via a serotonin receptor at EECs. This was studied by analyzing
serotonin, GLP-1, PYY and CCK release from intestinal tissue segments
after exposure to a lipid mixture (safﬂower oil), protein (casein),
carbohydrate (sucrose) and a non-caloric sweetener (rebaudioside A).
Next, the role of serotonin on GLP-1 release from intestinal
segments was studied using the selective serotonin re-uptake
inhibitor (SSRI) ﬂuoxetine. Fluoxetine inhibits serotonin re-uptake
that is mediated by the membrane embedded serotonin reuptake
transporter [12]. Two different models were used; an ex vivo and
in vitromodel. First, porcine intestinal segmentswere applied because
these conglomerates of multiple cell types such as EECs, ECCs, and
absorptive enterocytes offer a suitable system to study cellular
interactions involved in serotonin and GLP-1 release. Second,
serotonin-stimulated GLP-1 release was studied using the murine
enteroendocrine STC-1 cell line [11]. STC-1 cells were exposed to
serotonin and the non-speciﬁc receptor antagonist asenapine or the
speciﬁc 5-HT3 receptor antagonist ondansetron.
2. Material and methods
2.1. Chemicals
Casein (food grade containing sodium, purityN82%, batch number 15,156) was
obtained from Dutch Protein Services BV (Tiel, The Netherlands). Rebaudioside A (food
grade, purityN97%, batch number 20,110,301, Chemspider ID 5294031) was obtained
from SteviJa Natuurlijk BV (Drachten, The Netherlands). Sucrose (food grade,
purityN99.9%) was supplied by Suiker Unie (Oud Gastel, The Netherlands). Safﬂower
oil (food grade, composed of 3% C16:0, 2–5% C18:0, 9–15% C18:1 and 75–85% C18:2)
was provided by De Wit Specialty Oils (De Waal, The Netherlands). Safﬂower oil was
emulsiﬁed as described previously [17,24,29] using potassium caseinate (1% w/v),
xanthan gum and guar gum (both 0.1%w/v, GF supplies, Amsterdam, The Netherlands).
Asenapine maleate (purityN98%), 5-hydroxytryptamine hydrochloride (serotonin,
purityN98%), ﬂuoxetine hydrochloride, L-ascorbic acid (purityN99%), pargyline
hydrochloride and phenylmethanesulfonyl ﬂuoride (PMSF) were obtained from
Sigma Aldrich (Zwijndrecht, The Netherlands). Chemicals to prepare the Krebs-Ringer
bicarbonate (KRB) buffer were: D-glucose (10 mM), magnesium chloride (0.2 mM),
potassium chloride (4.6 mM) sodium chloride (119.2 mM), sodium phosphate dibasic
(0.7 mM) sodium phosphate monobasic (1.3 mM), and HEPES (25 mM) were all
obtained from Sigma Aldrich (Zwijndrecht, The Netherlands). Hanks' Balanced Salt
Solution (HBSS) was obtained from Life technologies Europe BV (Bleiswijk, The
Netherlands) and was supplemented with 10 mMHEPES (Merck Millipore, Darmstadt,
Germany). Lonza (Verviers SPRL, Belgium) providedDulbecco'sModiﬁed EagleMedium
(DMEM), fetal calf serum (FCS). The pH of both the buffers was adjusted to pH 7.4 and
both buffers contained 1 mM L-ascorbic acid and 100 μM pargyline to prevent
oxidation and metabolism of serotonin by monoamine oxidase as described previously
[18]. All nutrient solutions were prepared fresh before incubation with the segments
and their pH was checked and adjusted to 7.4 if necessary.
2.2. Collection of porcine intestinal tissues
Intestinal tissues were obtained from 10 male pigs (Sus scrofa domesticus),
considered healthy after evaluation by a veterinarian. The protocol for this study was
approved by the Animal Ethics Committee Utrecht (Ethics Committee Permit Numbers
2014.I.01.001 and 2014.I.06.037, Utrecht, The Netherlands). The pigs had a mean (±
SEM) body mass of 88±4 kg and a mean age of 6 months. Pigs were housed in groups,
fed ad libitumwith a standard pig diet (Vitaal P 003103, de Heus, Ede The Netherlands)with free access to water. The pigs were killed by a veterinarian through an intracardial
injection of Euthanimal (pentobarbital 40%, 30 ml per pig) (Alfasan, Woerden, NL).
Within approximately 5 min after the pigs were killed, the intestines were excised, and
intestinal tissue of about 1 m length of different anatomical regions were collected and
stored in ice-cold oxygenated (95% O2, 5% CO2) KRB buffer. Duodenal tissue was
collected at 10 cm below the pylorus, jejunal tissue was collected 4.5 m proximal from
the ileocaecal junction and ileal tissuewas collected at 1 mproximal from the ileocaecal
junction. Tissues were transported to the laboratory and immediately used for ex vivo
experiments.
The time between excision and start of the experiments did not exceed 30 min. To
determine the intracellular concentrations of serotonin, CCK, GLP-1 and PYY whole
tissue segments (0.5 cm2) from duodenal, jejunal and ileal tissue were immediately
snap frozen and stored below−70 °C.
2.3. Stimulation of intestinal segments with casein, safflower oil, sucrose and rebaudioside A
Concentrations of the nutrient stimuli chosen are within the physiological range
and these concentrations previously showed to stimulate GLP-1 release in the same
porcine intestinal segmentmodel [24]. Incubations of porcine intestinal tissue segments
with casein (1%w/v), rebaudioside A (12.5 mM), sucrose (50 mM), safﬂower oil (3.35%
w/v), serotonin (30 μM) and ﬂuoxetine (0.155 μM) alone, or in the presence of
ﬂuoxetine (0.155 μM) were performed as described previously [24]. In brief, upon
arrival at the laboratory the intestine was rinsed with ice-cold oxygenated KRB buffer
and cut open in a longitudinal direction. The outermuscle layerswere carefully stripped
off with the basolateral side upward. Themucosal tissuewas placedwith the apical side
upward, and circles of tissue with a diameter of 8 mm (about 0.5 cm2) were punched
out using a disposable biopsy punch (Medline Industries, Inc. Mundelein, Illinois, USA).
Intestinal segments of duodenal and ileal tissue were used for the incubation
experiments. The intestinal segments were transferred to a 48-wells plate which was
ﬁlled with 500 μL ice-cold KRB buffer per well, and kept on ice until the start of the
experiment. Thereafter, the tissues were brought to room temperature within 30 min,
followed by a preheating step at 37 °C for 1 h in a humidiﬁed incubator (95% O2, 5% v/v
CO2). Within the time of this preheating step all tissue segments exposed to the SSRI
ﬂuoxetine were pre-incubated with ﬂuoxetine, 30 min before the actual incubation
started, by replacing the KRB buffer with KRB buffer in which ﬂuoxetine had been
dissolved. The concentrations ﬂuoxetine (0.155 μM) and serotonin (30 μM) used were
selected based on pilot experiments analyzing tissue uptake of radiolabeled serotonin
and GLP-1 release after exposure to various concentrations of ﬂuoxetine and serotonin,
and on a previous study showing an IC50 for ﬂuoxetine of 0.0155 μM in Caco-2 cells [18].
To study the release of serotonin, CCK, PYY and GLP-1, incubationswere initiated by
replacing the KRB buffer solution with preheated (37 °C) isosmotic KRB buffer without
D-glucose containing the test compounds. KRB buffer without D-glucose was used as a
control since D-glucose might induce gastrointestinal hormone release. Next, the tissue
was put in a humidiﬁed incubator for either 5, 10, 20 or 60 min at 37 °C (5% (v/v) CO2).
After incubation (5, 10, 20 and 60 min) samples of incubation media were collected,
mixed with 100 μM PMSF to inactivate dipeptidyl peptidase IV, aliquoted and
either stored at 4 °C for further analysis of lactate dehydrogenase (LDH) or stored
below−70 °C for further analysis of serotonin, CCK, GLP-1 and PYY.
Tissue viability was checked by measuring the leakage of intracellular LDH as
described before [24,31] using an LDH kit (Sigma Aldrich, Zwijndrecht, the
Netherlands). LDH activity in the supernatant was expressed as a percentage of the
total LDH activity present in control tissue collected before incubation. Total tissue
levels of LDH and intracellular serotonin, CCK, GLP-1 and PYY were determined in
0.5 cm2 tissue segments of duodenum, jejunum, and ileum, which were homogenized
in ice-cold KRB buffer containing 100 μmol/L PMSF with a Potter Elvehjem type Teﬂon
pestle tissue grinder (Braun, Melsungen, Germany) for 5 min at 200 rounds perminute.
Samples were only included for further analysis when LDH leakage did not exceed 10%
of the total LDH tissue content. No samples had to be excluded on the basis of this
criterion.
2.4. Incubation of STC-1 cells with serotonin
STC-1 cells, a murine pluripotent enteroendocrine cell-line, were cultured in
Dulbecco's modiﬁed Eagle's medium containing 10% fetal calf's serum (Life Technol-
ogies Europe BV., Bleiswijk, NL) and 1% Penicillin–Streptomycin (Lonza, Verviers, BE).
For the GLP-1 secretion experiments the cells were grown in a 24-wells plate. Upon
reaching 80% conﬂuence, medium was washed and replaced by Hank's balanced salt
solution (HBSS) (Life Technologies Europe BV., Bleiswijk, NL) with serotonin (0, 10, 30
and 100 μM). STC-1 cells were incubated with serotonin (0, 30 μM) in the presence and
absence of asenapine (0, 1 and 10 μM) a non-speciﬁc serotonin receptor antagonist [26]
and in the presence and absence of ondansetron (0, 1 and 10 μM) a speciﬁc 5-HT3
receptor antagonist [5,28] to investigate whether serotonin-stimulated GLP-1 release is
mediated through a receptor-mediated process. The concentrations asenapine and
ondansetron were chosen based on literature data [5,26,28]. Cells were pre-incubated
with either asenapine or ondansetron for 30 min in a humidiﬁed incubator (37 °C; 95%
O2, 5% v/v CO2). After pre-incubation, medium was replaced by HBSS containing test
compounds and incubated for 2 h. Media samples were collected, PMSF (100 μM) was
added and sampleswere stored at−20 °C for GLP-1 analysis. Cell viabilitywas analyzed
by measuring leakage of intracellular lactate dehydrogenase (LDH) into the media, and
Fig. 1. GLP-1, PYY and CCK released from intestinal tissue segments after exposure to
various nutrients and rebaudioside A. Ileal GLP-1 (A), ileal PYY (B) and duodenal CCK
(C) released from intestinal segments after exposure to KRB buffer, sucrose, casein,
safﬂower oil or rebaudioside A.$Pb .05 release is increased over time as compared to KRB
buffer, ^Pb .05 release is increased over time as compared to safﬂower oil,! Pb .05 release
is increased over time as compared to sucrose, *Pb .001 release is increased as compared
to KRB buffer at the same time point, #Pb .05 release is increased as compared to
safﬂower oil at the same time point.
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leakage did not exceed 10%. Furthermore, cell viabilitywas checked by neutral red assay
[23]. None of the test conditions affected cell viability.
2.5. Gene expression analysis of STC-1 cells
STC-1 cells were grown to 80% conﬂuence and incubated for 2 h in HBSS. RNA was
isolated by using TRIzol reagent (Life technologies, Bleiswijk, Netherlands) and RNeasy
micro kit. One hundred nanogram of RNA was used for Whole Transcript cDNA
synthesis (Affymetrix, inc. Santa Clara, USA). Hybridization, washing and scanning of
Affymetrix GeneChip Mouse Gene 1.1 ST arrays was carried out according to standard
Affymetrix protocols. Arrays were normalized using the Robust Multi-array Average
(RMA) method [2,13]. Probe sets were assigned to unique gene identiﬁers, in this case
Entrez IDs. The probes on theMouse Gene 1.1 ST arrays represent 21,213 Entrez IDs [7].
Array data were analyzed using an in-house, on-line system [15].
2.6. Serotonin, CCK, GLP-1 and PYY analysis
Serotonin was analyzed according to instructions of the manufacturer by a
commercially available enzyme-linked immunosorbent assay (ELISA) (BA E-5900;
Labor Diagnostika Nord GmbH & Co. Germany), using a BioTek Synergy HT absorbance
microplate reader (BioTek Instruments, Inc. Winooski, VT, USA). The detection range of
this assay is 0.015–2.5 ng/mL. The inter-assay coefﬁcient of variation (CV) of this kit is
18% and the intra-assay variation is 14%. If necessary, samples were diluted with assay
buffer to obtain concentrations within the detection range of this kit.
Concentrations of CCK-8 (CCK 26–33) were analyzed with an optimized and
validated commercial human RIA kit (EURIA-CCK, RB302, Euro-diagnostica, Malmö,
Sweden). An identical sequence of CCK-8 has been found for most mammals, among
them pig and man. This improved assay system has been optimized to reach a high
sensitivity of 0.05 pM and does not have cross-reactivity with gastrin-17 or sulfated
gastrin. The intra-assay CV was 8.9% at a concentration of 0.84 pM and 4.9% at a
concentration of 1.98 pM. Radioactivity of [125I]-CCK-8 was measured by liquid
scintillation counting using a gamma counter (EC&G, Breda, The Netherlands).
Active GLP-1 (7–36)was determined using a Glucagon Like Pepide-1 (Active) ELISA
kit (EGLP-35 K, Millipore, Linco Research, Billerica, MA, USA) according to the
manufacturer's instructions. Since the GLP-1 hormone gene sequence is highly
preserved, this kit can be applied for analyzing porcine GLP-1. The range of this assay
is 2–100 pM. The inter-assay CV is 11% and the intra-assay CV is 6%. When necessary,
samples were diluted in assay buffer from the kit to bewithin the detection range of this
assay.
PYY releasewas analyzed by a commercially available ELISA kit for total porcine PYY
(Bachem, Penisula Laboratories, San Carlos, CA, USA) according to the manufacturer's
instructions. This kitmeasures porcine PYY, and the range of this assay is approximately
4.6–150 pM. The inter-assay CV is 6% and the intra-assay CV is 3%. Itwas not necessary to
dilute samples for this assay.
2.7. Statistical analysis
Statistical analysis was performed using the SAS statistical software package (SAS
version 9; SAS Institute, Cary, NC, USA). All variables, serotonin, CCK, GLP-1 and PYY
were compared with a mixed analysis of variance (ANOVA) model. Data were visually
checked on normality and on constant variance of residuals by plots of residuals vs.
corresponding predicted values. If data was not normally distributed, log transforma-
tion was applied for further analysis of the data as was the case for CCK, GLP-1 and
serotonin. For the intestinal segment experiments the statistical model included the
ﬁxed factors time (5, 10, 20 and60 min), location (duodenumand ileum) and treatment
(control, casein, safﬂower oil, sucrose, rebaudioside A, serotonin, ﬂuoxetine, casein and
ﬂuoxetine, safﬂower oil and ﬂuoxetine, sucrose and ﬂuoxetine, rebaudioside A and
ﬂuoxetine, serotonin and ﬂuoxetine). Because all incubations were performed using
intestinal tissue obtained from the same pig, intervention effects within the intestine of
one pig were compared by including the random factor pig, which speciﬁes the
individual pig. For the STC-1 cell experiments the statisticalmodel includedﬁxed factors
serotonin (0 and 30 μM) and asenapine (0, 1 and 10 μM). A post hoc test with Tukey–
Kramer adjustment was used if an signiﬁcant effect occurred. Data are presented as the
mean ± SEM and differences are considered signifcant at Pb .05.
3. Results
3.1. Intestinal hormone concentrations in tissue segments and effects of
nutrients and rebaudioside A on GLP-1, PYY and CCK release
GLP-1 tissue concentrations were highest in ileum followed by
jejunum and duodenum (0.3±0.1, 6.7±0.7, 10.5±1.2 pmol/cm2
tissue in duodenum, jejunum, and ileum, respectively). PYY concen-
trations in tissue were highest in jejunum followed by ileum and
duodenum (1.1±0.4, 7.7±1.0, 4.3±0.8 pmol/cm2 tissue, for duode-num, jejunum and ileum, respectively) and CCK intestinal tissue
concentrations were highest in duodenum followed by jejunum and
ileum (12.8±1.6, 1.5±0.3, and 0.27±0.1 pmol/cm2 tissue, for
duodenum, jejunum and ileum, respectively).
The effects of casein, sucrose, safﬂower oil and rebaudioside A on
GLP-1, PYY and CCK release from ileal and duodenal segments are
presented in Fig. 1. The effects on GLP-1 release from ileal segments
were themost pronounced (Fig. 1A). Casein, sucrose and rebaudioside
A all induced a marked GLP-1 increase (Pb .001). The effect of
safﬂower oil was less pronounced (Pb .05). Casein and rebaudioside
A also increased ileal GLP-1 release as compared to safﬂower oil
(Pb .05). Nutrients and rebaudioside A did not stimulate GLP-1 release
from duodenal segments (data not shown).
None of the nutrients stimulated PYY release from ileal segments as
compared to control. Casein increased ileal PYY release as compared to
sucrose and safﬂower oil (Pb .05; (Fig. 1B)). Nutrients and rebaudioside A
did not stimulate PYY release fromduodenal segments (data not shown).
None of the nutrients stimulated CCK release from duodenal
segments as compared to control. Casein and rebaudioside A increased
CCK release (Fig. 1C) as compared to exposure to sucrose and safﬂower
Fig. 2. GLP-1 released from ileal tissue segments after exposure to serotonin.$Pb .05 GLP-
1 release is increased over time as compared toKRB buffer. *Pb .001 signiﬁcant increased
GLP-1 release as compared to KRB buffer at the same time point.
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ileal CCK release (data not shown).3.2. Serotonin stimulates GLP-1 release from ileal tissue segments and
enteroendocrine cells
Serotonin increased GLP-1 release from ileal segments several fold
over time (Pb .001) (Fig. 2A). Incubation with serotonin did not
change PYY release nor CCK released from both ileal and duodenal
tissue segments (data not shown).
The role of serotonin on GLP-1 releasewas further explored in STC-
1 cell experiments. Serotonin (30 and 100 μM) stimulated GLP-1
release from STC-1 cells as compared to control and to 10 μM
serotonin (Pb .001) (Fig. 3A). Serotonin-stimulated GLP-1 release
was inhibited by the non-speciﬁc serotonin receptor antagonist
asenapine (Fig. 3B). Effects were signiﬁcant at 10 μM asenapine
(Pb .05) but not at 1 μMasenapine (P=.07). Exposure of STC-1 cells to
asenapine alone did not affect GLP-1 release. Ondansetron (1 andFig. 3. GLP-1 released from STC-1 cells after exposure to serotonin (A), GLP-1 released in the
absence and presence of the non-speciﬁc serotonin receptor antagonist asenapine (B) (n=
3). **Pb .001 increased GLP-1 release as compared to 0 and 10 μM serotonin. *Pb .01 GLP-1
release is decreased as compared to 30 μM serotonin. #P=.07 1 μM asenapine tended to
inhibit serotonin-stimulated GLP-1 release.10 μM) a speciﬁc 5-HT3 receptor antagonist had no effect on
serotonin-stimulated GLP-1 release (data not shown). (See Fig. 4.)
Analysis of the gene expression in STC-1 cells (N=3) showed an
average RMA intensity of 344±9 for serotonin receptor 1b. Further-
more, therewas a very low expression of serotonin receptor 5b, which
had an average RMA intensity of 24±1. The other serotonin receptors
(1a, 1d, 1f, 2a,2b,2c, 3a,3b,4, 5a,6 and 7) and SERT (SLC6a4) were
expressed below the detection threshold of 20.3.3. Serotonin intestinal tissue concentrations and induction of it's
release following exposure to casein and safflower oil
Tissue concentrations of serotonin showed a different distribution
pattern over the small intestine compared to that of GLP-1, PYY and CCK.
Tissue concentrations of serotonin were highest in duodenum, followed
by ileum and jejunum (2463±363, 884±202, and 1371±154 pmol/
cm2 tissue for duodenum, jejunum and ileum, respectively).
To study the effect of (non-)nutritional stimuli on serotonin release
from intestinal epithelium, concentrations of serotonin secreted in the
medium were analyzed after exposure of the tissues to casein, safﬂower
oil, sucrose and rebaudioside A. Casein and safﬂower oil caused increased
serotonin concentrations in media over time (Pb .001) (Fig. 4), with
media concentrations from duodenum approximately 10 times higher as
compared to media concentrations from ileum (Pb .001). Duodenal andFig. 4. Serotonin released from duodenal (A) and ileal (B) tissue segments after exposure to
various nutrients and rebaudioside A. Duodenal (A) and ileal (B) serotonin released from
intestinal segments after exposure toKRBbuffer, sucrose, casein, safﬂoweroil or rebaudioside
A. ***Pb .001 release is increased over time as compared to KRB buffer, *Pb .001 release is
increased as compared to KRB buffer at the same time point.
Fig. 5. Serotonin released from duodenal (A and B) and ileal (C and D) tissue segments after exposure to casein and safﬂower oil in the presence and absence of ﬂuoxetine. Duodenal (A
and B) and Ileal (C and D) serotonin concentrations in incubation media after exposure to KRB, ﬂuoxetine, casein, casein + ﬂuoxetine, safﬂower oil and safﬂower oil + ﬂuoxetine.
*Pb .001 increased as compared to KRB buffer at the same time point, $Pb .001 increased as compared toﬂuoxetine at the same time point, ^Pb .001 increased as compared to casein at the
same time point.
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sucrose and rebaudioside A (Fig. 5).
3.4. SERT inhibition augments casein- and safflower-stimulated
serotonin release
Blocking the cellular reuptake of serotoninwithﬂuoxetine resulted
in increased serotonin concentrations in the medium from duodenal
segments after 60 min (Pb .001) (Fig. 5A). Fluoxetine induced a
smaller effect on serotonin concentrations inmedium from ileal tissue
segments, these concentrations being increased after 20 min only
(Pb .05) (Fig. 5B).
The combination of ﬂuoxetine and casein increased serotonin
medium concentrations from duodenal and ileal tissue incubations as
compared to ﬂuoxetine alone (Pb .001) and casein alone (Pb .05 at
10 min) (Fig. 5). Combining ﬂuoxetine with safﬂower oil increased
serotonin medium concentrations from duodenum and ileum as
compared to ﬂuoxetine alone (Pb .001) (Fig. 5).
The combination of rebaudioside A and ﬂuoxetine increased
duodenal serotonin concentrations in medium only after 10 min as
compared to rebaudioside A (Pb .001). However, serotonin concen-
trations in medium of ileum did not change after exposure to the
combination of rebaudioside A and ﬂuoxetine (data not shown). The
combination of sucrose and ﬂuoxetine did not change serotonin
concentrations in themedia of both duodenal and ileal segments (data
not shown).
3.5. SERT inhibition increases nutrient- and rebaudioside A-stimulated
GLP-1, PYY and CCK release
Fluoxetine alone increased GLP-1 release (Pb .001), whereas ileal
PYY and duodenal CCK release were not changed. The combination ofcasein and ﬂuoxetine increased GLP-1 (Pb .01), PYY and CCK release
over time (Pb .001) (Fig. 6). For the other combinations of nutrients
and sweetener with ﬂuoxetine no time and treatment interactions
were found. However, since the release of GLP-1, PYY and CCK tended
to be increased by the addition of ﬂuoxetine as compared to nutrient
exposure alone, total area under the curves (AUC) were calculated.
Overall, the combination of ﬂuoxetine with the nutrients tested and
with rebaudioside A resulted in increased AUCs of GLP-1 (Fig. 7), PYY
and CCK release vs nutrients alone (Pb .01).
4. Discussion
In our study we showed that GLP-1 release from intestinal ileal
tissue following stimulation by different (non-)nutritional stimuli
could be further augmented by adding the serotonin reuptake
inhibitor ﬂuoxetine. Next to this, serotonin itself stimulated GLP-1
release from ileal tissue segments and from STC-1 cells. The latter was
inhibited by the non-speciﬁc serotonin receptor antagonist asenapine
suggesting a receptor-mediated process.
All nutrients and mixtures tested as well as the non-caloric
sweetener rebaudioside A stimulated GLP-1 release from intestinal
ileal tissues, which conﬁrmed our previous ﬁndings using the same
intestinal segment model [24]. These data correspond to ﬁndings in
vivo as well, since ileal delivery of the same ‘non-predigested’
macronutrients resulted in increased satiation and satiety hormone
release [29]. For rebaudioside A, however, it is not known if this
stimulates GLP-1 release in vivo as well and hence induces satiation.
Another study demonstrated satiating properties of stevia in vivo [1]
whereas other sweeteners including sucralose did not affect satiety
hormone release in vivo [10,27].
In the experiments described here, time-dependency of satiety
hormone release was studied. Compared to our previous study we
Fig. 6. GLP-1, PYYandCCKreleased fromintestinal tissuesegmentsafterexposure tocasein in
the presence and absence of ﬂuoxetine. Ileal GLP-1 (A), ileal PYY (B) and duodenal CCK (C)
released after exposure to KRB buffer, ﬂuoxetine, casein or the combination of casein and
ﬂuoxetine. $Pb .05 release is increased over time as compared to KRB buffer. *Pb .001
increased release as compared to KRB buffer at the same time point.
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to buffer only. It is unlikely that this effect is due to tissue damage,
since LDH leakage was below 10%. CCK release from duodenal
segments was analyzed for the ﬁrst time using this ex vivo model.
Surprisingly, rebaudioside A and casein stimulated CCK release only
when compared to sucrose and safﬂower oil, but not when compared
to control. Safﬂower oil was expected to increase CCK, as it was shown
before that intraduodenal lipid infusions resulted in increased CCK
levels in vivo [25]. In the latter study, lipid infusions of mixtures of
linoleic, oleic and palmitic acid were used.
Overall, the results of the present study illustrate that the ex vivo
model being a conglomerate of multiple cell types such as EECs, ECCs
and absorptive enterocytes, offers a suitable system to study the
cellular interactions involved in serotonin and GLP-1 release.
It is known that nutrient sensing GPCRs and ion-dependent
nutrient transporters at EECs play a major role in nutrient-stimulated
GLP-1, PYY and CCK release [15,21]. However, not for all nutrients
stimulating GLP-1, PYY or CCK release, a receptor is known. We
hypothesized that nutrient-receptor interaction results in serotonin
release, and that this released serotonin enhances nutrient-stimulated
GLP-1 release. A hypothetic model for this effect is depicted in Fig. 8.
The proposed mechanism by which serotonin may contribute to
receptor-mediated GLP-1 release is; 1) nutrients stimulate serotonin
release from ECCs via interaction with GPCR receptors on ECCs [14],
subsequently 2) this released serotonin stimulates the release of GLP-
1 from EECs via a serotonin receptor-mediated process. This
hypothesis is supported by the data found in the present study. We
showed that nutrients stimulated serotonin release from ileal tissue
segments and that serotonin stimulatedGLP-1 release from ileal tissue
segments. Also in the enteroendocrine STC-1 cell model, serotonin
stimulated GLP-1 release which could be inhibited by a non-speciﬁc
serotonin receptor agonist asenapine. Asenapine has binding afﬁnities
for various serotonin receptors including the 5HT1a, 5-HT1b, 5-HT2a, 5-
HT2b, 5-HT2c, 5-HT5, 5-HT6 and 5-HT7 receptor [26]. It should be noted
that this antagonist has binding afﬁnities for other receptors such as
adrenoreceptors and dopamine receptors as well [26]. However,
because asenapine inhibited GLP-1 release after stimulation with
serotonin, we believe this effect to be mediated via serotonin
receptors. In contrast to asenapine, ondansetron, a speciﬁc 5-HT3
receptor antagonist did not inhibit serotonin-stimulatedGLP-1 release
from STC-1 cells. This suggests that receptors other than the 5-HT3
receptor mediate serotonin-stimulated GLP-1 release. A potential
candidate may be the 5-HT1b receptor. Asenapine has afﬁnity for this 5-
HT1b receptor. A recent report also showed that stimulation of 5-HT1b
receptors with speciﬁc 5-HT1b agonists enhanced GLP-1 plasma concen-
trations in mice [20]. Further studies are needed to identify the speciﬁc
serotonin receptors involved in serotonin-stimulated GLP-1 release.
This study has also limitations that warrant discussion. First, the
data presented support the idea that serotonin contributes to
nutrient-stimulated GLP-1 release, whereas the effects on CCK and
PYY were less convincing. Such an effect may relate to serotonin
receptor distribution in the small intestine. Possibly, serotonin
receptors on GLP-1 containing L-cells in the ileum are more abundant
than those on EECs containing PYY, or CCK in the duodenum.
Remarkable though was that serotonin release and tissue concentra-
tions were highest in duodenum. Therefore, more studies are needed
to investigate serotonin receptor expression on EECs and to study the
relation between activation of speciﬁc serotonin receptors and GLP-1,
PYY and CCK release. Additionally, it should be noted that this segment
model does not distinguishes between the apical and basolateral side.
It can therefore not be excluded that the apical or basolateral side
reacts differentially to the nutrients.
Second, there was no control for potassium caseinate alone.
Safﬂower oil was prepared as described previously in order to
compare results between studies [17,24,29]. It has been shown thatthe same concentration of potassium caseinate (1%w/v) did not affect
CCK, PYY concentrations nor satiety in vivo [13]. However, in our
previous and current study using the same ex vivo segment model
[24], we showed that another type of casein in the same concentration
(1%w/v) already induced GLP-1 release. Therefore, we cannot exclude
the possibility that the potassium caseinate (1% w/v) used to emulsify
the safﬂower oil contributed to the effects found for safﬂower oil.
Future studies should therefore always include a control for the added
potassium caseinate in safﬂower oil.
Third, sucrose and rebaudiosideAboth stimulatedGLP-1 release and
this GLP-1 release was further stimulated after inhibition of serotonin
reuptake. However, serotonin release was not stimulated by these
compounds. It was expected that sucrose and rebaudioside A would
result in serotonin release since other studies showed that odorants and
tastants other than rebaudioside A stimulated serotonin release from
enterochromafﬁn cells [3,14]. Possibly, the turn-over of serotonin is so
high that quantities of serotonin accumulated in the incubation media
were too low to be detected. It would be interesting to use alternative
methods to provide more insight in the timing and sequence of the
release of serotonin and satiety hormones. One interesting method is
amperometrical recording [4], which has been applied to measure
serotonin release from rabbit ileal mucosa and from ECCs [3,21].
Fig. 7. GLP-1, PYY and CCK released from intestinal segments after exposure to various nutrients and rebaudioside A in the presence and absence of ﬂuoxetine. Area under the curves
(AUCs) of ileal GLP-1 (A), ileal PYY (B) and duodenal CCK (C) released after exposure to various stimuli with and without ﬂuoxetine. The AUCs of CCK, PYY and GLP-1 are increased by
SERT inhibition as compared to stimuli exposure alone ﬂuoxetine effect Pb .01.
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enhanced nutrient-stimulated GLP-1, PYY and CCK release from
intestinal segments. However, the additional effect of ﬂuoxetine was
only small in comparison to hormone release induced by the nutrients
alone, possibly due to the fact that there was already a copious release
of serotonin in the epithelial space. Further studies are needed to
investigate the magnitude of serotonin's contribution to nutrient-
stimulated GLP-1 release.Collectively, our data suggest an additional mechanism for nutrient-
stimulated GLP-1 release via the release of serotonin by ECCs. Serotonin
present in the small intestine contributes to the enhancement of GLP-1
release by responding to macronutrients, possibly via the activation of
serotonin receptors on EECs. This additional mechanism contributes to
the idea that nutrient sensing in the small intestine is regulated by
interaction of multiple cells that respond to nutrient ﬂuctuations in
order to optimize food digestion and regulation of food intake.
Fig. 8. Proposed mechanism of serotonin modulating GLP-1 release from the ileum. This cartoon illustrates the following hypothesis; dietary compounds such as casein, safﬂower oil,
sucrose or rebaudioside Amay stimulate GLP-1 release from an EEC via interactionwith a GPCR (A), simultaneously caseinmay stimulate extra-intestinal serotonin concentrations from
ECC via interaction with a GPCR (B). Consequently this induced serotonin release may stimulate (additional) GLP-1 release via interaction with an 5-HT receptor on EEC (C).
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ANOVA mixed analysis of variance
CaSR Calcium sensing receptor
CCK cholecystokinin
ECC enterochromafﬁn cell
EEC enteroendocrine cell
GLP-1 glucagon-like peptide-1
GPCR G-coupled protein receptors
GI gastrointestinal
HBSS Hanks' Balanced Salt Solution
KRB Krebs Ringer Bicarbonate
5-HT serotonin
LDH lactate dehydrogenase
PYY Peptide YY
PMSF phenylmethanesulfonyl ﬂuoride
SEM standard error of the mean
SD standard deviation
SSRI selective serotonin re-uptake inhibitor
T1R2 taste receptor type 1 member 2
T1R3 taste receptor type 1 member 3
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